Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.

Tanaka S, Kuroda T, Sugimoto T, Nakamura T, Shiraki M

Current medical research and opinion13 Jan 2014Cited by 14 (Europe PMC)

PMID24392946DOI10.1185/03007995.2013.879440PepBankPUB-24392946

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In severe osteoporosis, lumbar BMD increased 6.69% with teriparatide versus 0.28% with placebo.
In plain wordsIn severe osteoporosis, spine bone density increased more with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD
Study
n = 237
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Measurements
Lumbar BMD percentage change
6.69%
teriparatide group
Lumbar BMD percentage change
0.28%
placebo group
Source sentences
Summary
The percentage change in lumbar bone mineral density was 6.69% in the teriparatide group compared with 0.28% in the placebo group (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis was conducted using data from the Teriparatide Once-Weekly Efficacy Research trial, a randomized, double-blind, placebo-controlled trial for patients with severe osteoporosis in Japan.
Summary · context
A total of 237 subjects (placebo group, n = 130; teriparatide group, n = 107) were assessed at baseline and at 72 weeks.
Report a problemFND-2439294601
02HumanRandomized controlled trialEfficacy outcome
In severe osteoporosis, one vertebral fracture occurred with teriparatide versus 16 with placebo.
In plain wordsIn severe osteoporosis, fewer spine fractures occurred with teriparatide than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIncident vertebral fractures
Study
n = 237
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Measurements
Incident vertebral fractures
1 fractures
teriparatide group
Incident vertebral fractures
16 fractures
placebo group
Source sentences
Summary
One incident vertebral fracture occurred in the teriparatide group compared with 16 in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis was conducted using data from the Teriparatide Once-Weekly Efficacy Research trial, a randomized, double-blind, placebo-controlled trial for patients with severe osteoporosis in Japan.
Summary · context
A total of 237 subjects (placebo group, n = 130; teriparatide group, n = 107) were assessed at baseline and at 72 weeks.
Report a problemFND-2439294602
03HumanRandomized controlled trialEfficacy outcome
In severe osteoporosis, the unadjusted vertebral fracture hazard ratio for teriparatide versus placebo was 0.07.
In plain wordsIn severe osteoporosis, teriparatide had a lower unadjusted spine fracture hazard than placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUnadjusted vertebral fracture hazard ratio
Study
n = 237
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Measurements
Unadjusted vertebral fracture hazard ratio
0.07 hazard ratio
teriparatide vs placebo
Unadjusted hazard ratio 95% CI
0.01 to 0.56 hazard ratio
teriparatide vs placebo
Source sentences
Summary
The unadjusted and adjusted hazard ratios of the teriparatide group compared with the placebo group were 0.07 (95% confidence interval: 0.01 to 0.56) and 0.64 (95% confidence interval: 0.06 to 6.36), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis was conducted using data from the Teriparatide Once-Weekly Efficacy Research trial, a randomized, double-blind, placebo-controlled trial for patients with severe osteoporosis in Japan.
Summary · context
A total of 237 subjects (placebo group, n = 130; teriparatide group, n = 107) were assessed at baseline and at 72 weeks.
Report a problemFND-2439294603
04HumanRandomized controlled trialEfficacy outcome
In severe osteoporosis, the adjusted vertebral fracture hazard ratio for teriparatide versus placebo was 0.64 (95% CI 0.06 to 6.36).
In plain wordsIn severe osteoporosis, the adjusted spine fracture estimate for teriparatide versus placebo had a wide confidence interval.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedAdjusted vertebral fracture hazard ratio
Study
n = 237
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · 72 weeksAs given in this study (human).
Measurements
Adjusted vertebral fracture hazard ratio
0.64 hazard ratio
teriparatide vs placebo
Adjusted hazard ratio 95% CI
0.06 to 6.36 hazard ratio
teriparatide vs placebo
Source sentences
Summary
The unadjusted and adjusted hazard ratios of the teriparatide group compared with the placebo group were 0.07 (95% confidence interval: 0.01 to 0.56) and 0.64 (95% confidence interval: 0.06 to 6.36), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis was conducted using data from the Teriparatide Once-Weekly Efficacy Research trial, a randomized, double-blind, placebo-controlled trial for patients with severe osteoporosis in Japan.
Summary · context
A total of 237 subjects (placebo group, n = 130; teriparatide group, n = 107) were assessed at baseline and at 72 weeks.
Report a problemFND-2439294604

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyMechanism
In severe osteoporosis, lumbar BMD changes explained 83% or 66% of the teriparatide treatment effect, depending on method.
In plain wordsIn severe osteoporosis, spine bone density changes explained much of teriparatide's effect versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableBMD-mediated treatment effect
Study
n = 237
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Measurements
Proportion of treatment effect explained by lumbar BMD change
83%
Freedman's method
Proportion of treatment effect explained by lumbar BMD change
66%
Chen's method
Source sentences
Summary
The proportion of treatment effect explained by changes in lumbar bone mineral density was 83% (Freedman's method) and 66% (Chen's method).
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis was conducted using data from the Teriparatide Once-Weekly Efficacy Research trial, a randomized, double-blind, placebo-controlled trial for patients with severe osteoporosis in Japan.
Summary · context
A total of 237 subjects (placebo group, n = 130; teriparatide group, n = 107) were assessed at baseline and at 72 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2439294605
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyMechanism
In severe osteoporosis, adjusting for bone turnover markers did not notably change teriparatide versus placebo hazard ratios.
In plain wordsIn severe osteoporosis, adjustment for bone turnover markers did not notably change teriparatide versus placebo hazard ratios.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone turnover marker adjustment
Study
n = 237
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
There were no notable changes in hazard ratios if we adjusted for bone turnover markers.
2 context sentences(design, population, supporting numbers)
Summary · context
This analysis was conducted using data from the Teriparatide Once-Weekly Efficacy Research trial, a randomized, double-blind, placebo-controlled trial for patients with severe osteoporosis in Japan.
Summary · context
A total of 237 subjects (placebo group, n = 130; teriparatide group, n = 107) were assessed at baseline and at 72 weeks.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2439294606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.